Claims for Patent: 7,795,026

Summary for Patent: 7,795,026

Title:	Methods for obtaining human embryoid body-derived cells
Abstract:	The invention is directed to novel cells that are derived from human embryoid bodies. Such embryoid body-derived (EBD) cells are relatively uncommitted or progenitor (e.g., pluripotent) cells. EBD cells, while not immortal, display long-term proliferation in culture with a normal karyotype and can be cryopreserved and cloned. They can be efficiently transfected with retroviruses and lentivirus and genetically manipulated. Although they have a developmentally broad multilineage expression profile, they do not form tumors when injected into severe combined immunodeficiency (SCID) mice. As a result, EBD cells have a variety of uses, for example, in transplantation therapies.
Inventor(s):	Shamblott; Michael J. (Baltimore, MD), Gearhart; John D. (Baltimore, MD)
Assignee:	The Johns Hopkins University School of Medicine (Baltimore, MD)
Application Number:	09/767,421
Patent Claims:	1. A method of obtaining a human embryoid body derived (EBD) cell comprising: (a) culturing primordial germ cells in a media comprising human basic fibroblast growth factor and lacking leukemia inhibitory factor under conditions that allow formation of a solid or cystic embryoid body having a 3-dimensional morphology; (b) disaggregating the solid or cystic embryoid body under enzymatic conditions to provide a constituent cell or embryoid body derived (EBD) cell; and (c) culturing the EBD cell on a defined extracellular matrix, wherein the EBD cell forms disaggregated single cells upon dissociation from embryoid bodies (EB) and proliferates for at least 30 population doublings without being immortal under the conditions of step (a). 2. The method of claim 1 comprising selecting a single EBD cell from the EBD cells and culturing the single EBD cell to produce a clonal population of cells. 3. The method of claim 1 comprising culturing the EBD cell in a media selected from the group consisting of RPMI 1640 supplemented with 15% serum and media consisting essentially of hEGF, hydrocortisone, gentamicin, amphotericin-B, fetal bovine serum, VEGF, heparin, recombinant human IGF-1 and ascorbic acid. 4. The method of claim 3 comprising culturing the EBD cell in a media consisting essentially of hEGF, hydrocortisone, gentamicin, amphotericin-B, fetal bovine serum, VEGF, heparin, recombinant human IGF-1 and ascorbic acid. 5. The method of claim 1, wherein the matrix comprises one or more defined extracellular matrix components. 6. The method of claim 5, wherein the one or more defined extracellular matrix components are selected from the group consisting of collagen I and human extracellular matrix extract. 7. The method of claim 6, wherein the one or more defined extracellular matrix components are selected from the group consisting of collagen I and human extracellular matrix extract. 8. The method of claim 1 comprising culturing the EBD cells for at least 30 population doublings. 9. The method of obtaining a human EBD cell of claim 1, wherein the enzymatic conditions include collagenase, dispase, or both. 10. The method of claim 1, further comprising expanding the EBD cells on one or more defined extracellular matrix components. 11. The method of claim 10, wherein the one or more defined extracellular matrix components are selected from the group consisting of collagen I and human extracellular matrix extract.

Details for Patent 7,795,026

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2020-01-21